



Dear Colleagues,

Please find a list of upcoming research funding opportunities from private sponsors below. This month’s calendar includes several opportunities for which deadlines have not yet been announced – please check the sponsor’s website and the full Request for Proposals/Applications (RFP/RFA) once it is released for official deadlines. **Dates in blue with *** are anticipated deadlines based on last year’s annual grantmaking cycle. Please refer to the sponsor’s website for official dates when they are announced.

All LOIs and applications are due to Sponsored Programs Administration (SPA) 5 business days prior to the sponsor deadline.

If you are interested in applying for external funding, please complete the intake form at <https://www.bmc.org/external-funding>.

March 2025 Private Funding Opportunities Calendar

Sponsor	Mechanism	Area	Description	Amount	Deadline	Notes
Childhood Arthritis and Rheumatology Research Alliance	CARRA-Arthritis Foundation Large Grant: Advancing Committee Projects	Juvenile arthritis	This opportunity is available to support research projects prioritized by the CARRA 2023-2025 Research Agenda, including projects focused on revising and updating Consensus Treatment Plans (CTPs) . See RFP for full list of areas of focus.	\$100,000 over 2 years	Sponsor: 2/28 SPA: 2/21	The PI must be a current CARRA member; Up to 3 grants will be awarded
Childhood Arthritis and Rheumatology Research Alliance	JIA Pilot Translational Research Grant	Juvenile arthritis	This pilot grant supports research that utilizes the CARRA Registry and/or biorepository and is intended to address promising new JIA projects and/or pursue novel ideas in basic, clinical, and translational JIA research that will provide preliminary data for future grant applications from other agencies and programs.	\$175,000 over 2 years	Sponsor: 2/28 SPA: 2/21	The PI must be a current CARRA member; only 1 award will be made
Pediatric Cancer Research Foundation	Basic Science Research Grants	Pediatric cancer	These grants fund basic science, translational and/or clinical state of the art pediatric cancer research initiatives. These grants fund work that is the basis for childhood cancer research, helping to move science in the direction of improved treatments and eventually finding a cure. They are designed to move hypothesis-driven research into the clinic , providing support for important preclinical projects that are necessary to move a study from the pre-clinical arena into a clinical trial.	\$450,000 over 3 years	Sponsor: 3/1 (LOI)* SPA: 2/21	LOI submissions for 2025 will be announced in late January

Pediatric Cancer Research Foundation	Translational Research Grant	Pediatric cancer	These grants fund new research protocols and therapies that hold promise for improved outcomes and accelerate cures from the laboratory bench to the bedside of children and teens with high-risk cancers . This grant is given to single or multi-institutional programs that involve open, cancer clinical trials or consortia, and implement new approaches to therapy.	\$200,000 over 2 years	Sponsor: 3/1 (LOI)* SPA: 2/21	LOI submissions for 2025 will be announced in late January
Lung Cancer Research Foundation	Leading Edge Research Grant Program	Lung cancer	The goal of the LCRF Leading Edge Research Grant Program is to fund innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, early detection, disparities, and social determinants of health research .	\$150,000 over 2 years	Sponsor: 3/3 (LOI) SPA: 2/24	Applicants must have less than ten years of experience since their initial faculty appointment
Lung Cancer Research Foundation	Research Grant on Prevention and Early Detection in Lung Cancer	Lung cancer	This grant mechanism will support projects that seek to identify, characterize, treat or prevent resistance to lung cancer therapies . Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across histological subtypes of lung cancer and across the care continuum including newly designed targeted therapies and immunotherapies.	\$150,000 over 2 years	Sponsor: 3/3 (LOI) SPA: 2/24	Applicants must have less than ten years of experience since their initial faculty appointment
Lung Cancer Research Foundation	Minority Career Development Award (CDA) in Lung Cancer	Lung cancer	As minority applicants must overcome systemic and structural barriers due to race, ethnicity, country of origin, socioeconomic status, and/or language, many leave academia which further exacerbates the lack of diversity in Science, Technology, Engineering and Mathematics (STEM) and medical fields. The goal of the LCRF Minority Career Development Award (CDA) for Lung Cancer is to provide protected time and mentoring to these trainees .	\$150,000 over 2 years	Sponsor: 3/3 (LOI) SPA: 2/24	Applicants should be postdoctoral/clinical fellows or assistant professors within 10 years of completing their MD and/or PhD degrees
Lung Cancer Research Foundation	Innovative Therapeutic Strategies to Treat Lung Cancers Harboring HER2 Mutations and/or Other HER2 Alterations	Lung cancer	This grant mechanism will focus on the science behind HER2 alterations as oncogenic drivers of malignancy and/or the development of novel therapeutic approaches for patients with tumors harboring HER2 mutations and/or other HER2 alterations.	\$500,000 over 2 years	Sponsor: 3/3 (LOI) SPA: 2/24	The proposal must be associated with a clinical trial (ongoing or planned). The proposal must have a program of basic and/or translational work associated with the clinical trial
The American Urological Association Education and Research, Inc. and Pfizer	Improving the care process for patients with advanced prostate cancer	Advanced prostate cancer	This RFP intends to fund novel quality improvement projects that address barriers to optimal care for patients with APC , which include those with biochemical recurrence at high-risk for metastasis, nonmetastatic castration-resistant prostate cancer, low- or high-volume metastatic hormone-sensitive prostate cancer, and metastatic castration-resistant prostate cancer, including those with germline and somatic genomic alterations.	\$250,000 over 2 years	Sponsor: 3/11 SPA: 3/4	The total budget available to the RFP is \$1.5 million
The Sontag Foundation	Distinguished Scientist Award	Brain cancer	Funding to launch the careers of extraordinary scientists with the potential to make a significant impact in the field of brain cancer .	\$750,000 over 5 years	Sponsor: 3/12 SPA: 3/5	Highly competitive. Previous awardees are PhDs or MD/PhDs.
Brain & Behavior Research Foundation	Young Investigator Grant	Psychiatric disorders	The BBRF Young Investigator Grant provides support for the most promising young scientists conducting neurobiological research. The awards are intended to enable promising investigators to either extend research fellowship training or begin careers as independent research faculty. Basic and/or clinical investigators are supported, but research must be relevant to serious brain and behavior disorders such as	\$70,000 over 2 years	Sponsor: March TBA* SPA: TBD	(Anticipated) 2025 cycle not yet announced

schizophrenia, mood disorders, anxiety disorders or child and adolescent mental illnesses.

Neuroendocrine Tumor Research Foundation	Investigator Awards	Neuroendocrine tumor	The foundation seeks innovative and transformative research proposals in NETs to help bring the field closer to more effective therapies . They are equally interested in basic, translational and clinical research applications, and encourage collaborations between investigators with expertise in different fields. Prior research in NETs is not a prerequisite.	\$270,000 over 2 years	Sponsor: 3/18 (LOI)* SPA: 3/11	(Anticipated) 2025 cycle not yet announced. Medium-sized grants equivalent to an NIH R21.
Aligning Science Across Parkinson's	Scientific Track	Parkinson's disease	The CRN 2025 Scientific Track will focus on supporting high-priority, mechanism-focused projects to drive new ideas into the Parkinson's disease R&D pipeline . The core team leadership must include 3-5 PIs and at least 1 early-career investigator; at least 2 different disciplines should be represented and 2-5 institutions should be represented.	\$3,000,000 over 3 years	Sponsor: 3/20 (LOI) SPA: 3/13	This research network intends to establish teams comprising the best researcher expertise to address key knowledge gaps, regardless of their geographical location or institutional affiliation
Ovarian Cancer Research Alliance	Health Equity Research Grant	Gynecologic cancers	The objective of this grantmaking program is to support research projects that promote equity, inclusivity, and evidence-based approaches to overcome the barriers faced by marginalized communities with a focus on ovarian cancers and/or related gynecologic cancers.	\$200,000 over 2 years	Sponsor: 3/26 (LOI)* SPA: 3/19	(Anticipated) 2025 cycle will be announced in early February
Ovarian Cancer Research Alliance	Collaborative Research Development Grant	Gynecologic cancers	The purpose of this grantmaking program is to provide funds for ovarian cancer and/or related gynecologic cancers research projects that may involve several investigators within one institution or collaborations between groups in multiple institutions. Interdisciplinary collaborations are encouraged.	\$900,000 over 3 years	Sponsor: 3/26 (LOI)* SPA: 3/19	(Anticipated) 2025 cycle will be announced in early February
Melanoma Research Foundation	Established Investigator Awards	Melanoma	The MRF will offer 1) a grant focused on either defining lethal melanoma and/or identifying lethal melanoma biomarkers at the patient, tumor and/or blood level (e.g. patient risk stratifications, gene expression profiles, ctDNA monitoring etc.) in honor of Katie Morgan (Lethal Melanoma EIA or LM EIA) and 2) a grant focused on pediatric melanoma (PED EIA). For the LM EIA, the grant must be focused on either defining lethal melanoma and/or identifying lethal melanoma biomarkers at the patient, tumor and/or blood level. For the PED EIA, the grant must focus on any aspect of pediatric melanoma.	\$250,000 over 2 years	Sponsor: 3/31 SPA: 3/24	
Cystic Fibrosis Foundation	Clinical Pilot and Feasibility Award	Cystic fibrosis	The Clinical Pilot and Feasibility Award is intended to support a project involving human subjects or samples that will develop and test new hypotheses and/or new methods in research areas relevant to cystic fibrosis .	up to \$392,000 over 2 years	Sponsor: 4/3 (LOI) SPA: 3/27	The amount listed here includes a \$50,000 health equity supplement, which aims to advance knowledge of health disparities in cystic fibrosis.

Pulmonary Hypertension Association

[Health Disparities in PH Research Award](#)

Pulmonary hypertension

The purpose of the Pulmonary Hypertension Association's Health Disparities in PH Research Award is to support research that addresses **early diagnosis, education and improving clinical outcomes and treatments for people with pulmonary hypertension affected by health inequities**. Proposals should identify and address factors that affect health inequities in vulnerable populations and clinical subsets of patients, or **propose solutions to address areas of health disparities in PH**.

\$100,000 over 2 years

Sponsor: 4/30

SPA: 4/23